corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 19214

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

McConaghie A
Value-based pricing will not harm industry, says NICE chief
InPharm 2011 Feb 18
http://www.inpharm.com/news/148696/value-based-pricing-will-not-harm-industry-says-nice-chief


Full text:

NICE’s chief executive Sir Andrew Dillon says he believes plans to introduce value-based pricing of medicines will not have a negative effect on the pharma industry.

Dillon was appearing before the committee of MPs charged with scrutinising the government’s Health and Social Care Bill, which encompasses mammoth reform of the health service as well as the pricing of medicines.

When asked whether or not value-based pricing (VBP) would have a negative impact on the UK pharma industry, Sir Andrew said: “It is likely to be on a range of neutral to positive.”

He added: “It can be positive if it achieves the aim of the government’s proposals – achieves our ambition of providing a clearer signal to the pharmaceutical industry about the sorts of products and the sorts of disease areas that we really want the industry to concentrate on.”

Dillon added that the aims of the VBP proposal were ‘entirely laudable’: “To fix a price of a drug that reflects accurately the additional benefits it brings over current standard practice; and the plan calls for more transparency and more clarity in what the NHS regards as value for new treatments, so that there is greater predictability in the process for everybody.”

He reassured the cross-bench committee of MPs that NICE would continue its clinical and cost effectiveness appraisals, but would no longer issue final recommendations direct to the NHS.

“It will still be possible for prescribers and the public to see just where a new treatment really scores in terms of additional benefit compared with what is available at the moment.

“We need to wait and see what the outcome of the consultation is to see the final arrangements and then to make an assessment of their ultimate impact,” he added.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








Far too large a section of the treatment of disease is to-day controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudo-science...
The blind faith which some men have in medicines illustrates too often the greatest of all human capacities - the capacity for self deception...
Some one will say, Is this all your science has to tell us? Is this the outcome of decades of good clinical work, of patient study of the disease, of anxious trial in such good faith of so many drugs? Give us back the childlike trust of the fathers in antimony and in the lancet rather than this cold nihilism. Not at all! Let us accept the truth, however unpleasant it may be, and with the death rate staring us in the face, let us not be deceived with vain fancies...
we need a stern, iconoclastic spirit which leads, not to nihilism, but to an active skepticism - not the passive skepticism, born of despair, but the active skepticism born of a knowledge that recognizes its limitations and knows full well that only in this attitude of mind can true progress be made.
- William Osler 1909